LifeMine Therapeutics
Clinical-stage biopharmaceutical company developing precision small-molecule therapeutics by mining fungal genomic diversity. The company combines a large, deep-sequenced fungal strain collection with bioinformatics, machine learning, and synthetic/medicinal chemistry to identify genetically encoded small molecules and advance candidates into preclinical and clinical development, including a lead calcineurin activation inhibitor being developed for prevention of organ transplant rejection.
Industries
Nr. of Employees
medium (51-250)
LifeMine Therapeutics
Patents
Products
Top-down discovery platform for fungal-derived small molecules
A computational and experimental platform that mines fungal genomes to identify genetically encoded small molecules and predict their target and mechanism for rapid lead generation.
Clinical-stage calcineurin activation inhibitor (lead program)
A structurally and mechanistically novel small-molecule calcineurin activation inhibitor being developed for prevention of organ transplant rejection and immune-mediated disorders; advanced into first-in-human clinical testing.
Avatar-Rx
A top-down drug discovery platform that digitally analyzes fungal DNA for biosynthetic gene clusters and genetically encoded small molecules.
LIFE-001
A structurally and mechanistically novel, organ-sparing, immunophilin-independent calcineurin activation inhibitor (CNai) delivered as a long-acting injectable for the treatment of multiple immune-mediated disorders and organ transplant rejection.
LifeBank
A fully genomicized fungal strain collection comprised of 100,000 deep-sequenced wild-type fungi spanning over 25,000 species to digitally search for new drugs.
Top-down discovery platform for fungal-derived small molecules
A computational and experimental platform that mines fungal genomes to identify genetically encoded small molecules and predict their target and mechanism for rapid lead generation.
Clinical-stage calcineurin activation inhibitor (lead program)
A structurally and mechanistically novel small-molecule calcineurin activation inhibitor being developed for prevention of organ transplant rejection and immune-mediated disorders; advanced into first-in-human clinical testing.
Avatar-Rx
A top-down drug discovery platform that digitally analyzes fungal DNA for biosynthetic gene clusters and genetically encoded small molecules.
LIFE-001
A structurally and mechanistically novel, organ-sparing, immunophilin-independent calcineurin activation inhibitor (CNai) delivered as a long-acting injectable for the treatment of multiple immune-mediated disorders and organ transplant rejection.
LifeBank
A fully genomicized fungal strain collection comprised of 100,000 deep-sequenced wild-type fungi spanning over 25,000 species to digitally search for new drugs.
Expertise Areas
- Fungal genomics-driven drug discovery
- Small-molecule discovery and medicinal chemistry
- Translational immunology and transplant therapeutics
- Preclinical candidate optimization and CMC strategy
Key Technologies
- High-throughput fungal genome sequencing
- Biosynthetic gene cluster mining
- Embedded target gene (resistance-gene) prediction
- Machine learning and bioinformatics for genomics
News & Updates
Announcement of a $263M financing to accelerate clinical development of the company's lead calcineurin activation inhibitor.
Press release announcing dosing of the first participant in a Phase 1 trial for the lead immunosuppressive small-molecule candidate.
Announcement of a Series C financing round to fund company growth and development.
Announcement of a strategic drug discovery and development collaboration with a major pharmaceutical company.
Announcement of a Series B financing round.
Named by Fierce Biotech as one of the 'Fierce 15' biotech companies in 2022.
Announcement of a $263M financing to accelerate clinical development of the company's lead calcineurin activation inhibitor.
Press release announcing dosing of the first participant in a Phase 1 trial for the lead immunosuppressive small-molecule candidate.
Announcement of a Series C financing round to fund company growth and development.
Announcement of a strategic drug discovery and development collaboration with a major pharmaceutical company.
Announcement of a Series B financing round.
Named by Fierce Biotech as one of the 'Fierce 15' biotech companies in 2022.